~~<i id='5776783086'><strike id='5776783086'><tt id='5776783086'><pre id='5776783086'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：entertainment 2025-10-01 06:13:19 Page View：5641

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Vertex non
Next article： Medicare proposal to cover medical devices draws a mixed reaction

explore

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

Bernie Sanders is gearing up to subpoena pharma CEOs

Sen.BernieSandersisaskinghiscolleaguestoissueasubpoenaoftwopharmaceuticalcompanyCEOs.KevinDietsch/Ge

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

AstraZeneca bets AAV gene therapy will still deliver the goods

AlastairGrant/APSengChenghasbeenworkingingenetherapyfornearlyaslongasgenetherapyhasbeenafield.Asayou

WSS

hotspot

hotspot

focus

explore

AstraZeneca bets AAV gene therapy will still deliver the goods